Private equity firm GTCR has reached a deal worth €4.1 billion ($4.8 billion) to acquire Czech-based generic drugmaker Zentiva from Advent International, according to the Financial Times. The transaction has been finalized and is expected to be formally announced within days, though neither GTCR, Advent, nor Zentiva have commented publicly.
Advent originally acquired Zentiva in 2018 from French pharmaceutical company Sanofi for €1.9 billion, steering the business through a period of expansion. Today, Zentiva manufactures a broad portfolio of generic and over-the-counter medicines, employs more than 5,000 staff, and operates across 30+ countries.
The sale follows reports earlier this year that India’s Aurobindo Pharma had been competing to acquire Zentiva at a valuation of up to $5.5 billion, highlighting the strong global interest in the generic drugs sector.
Source: Reuters
